

To: [REDACTED] [REDACTED] [REDACTED] @pfizer.com]; [REDACTED] [REDACTED] [REDACTED] @its.inj.com]; [REDACTED] [REDACTED] [REDACTED] @fhi.no]; [REDACTED] [REDACTED] [REDACTED] @pfizer.com]; [REDACTED] [REDACTED] [REDACTED] @sanofi.com]; [REDACTED] [REDACTED] [REDACTED] @sanofi.com]; [REDACTED] [REDACTED] [REDACTED] @merck.com]; [REDACTED] [REDACTED] [REDACTED] @sanofi.com]; [REDACTED] [REDACTED] [REDACTED] @vaccineseuropa.eu]; [REDACTED] [REDACTED] [REDACTED] @gsk.com]; [REDACTED] [REDACTED] [REDACTED] @ucl.ac.uk]; [REDACTED] [REDACTED] [REDACTED] @umcg.nl]; [REDACTED] [REDACTED] [REDACTED] @pfizer.com]; [REDACTED] [REDACTED] [REDACTED] @ucl.ac.uk]; [REDACTED] [REDACTED] [REDACTED] @merck.com]; [REDACTED] [REDACTED] [REDACTED] @uibk.ac.at]; [REDACTED] [REDACTED] [REDACTED] @p-95.com]; [REDACTED] [REDACTED] [REDACTED] @rivm.nl]; [REDACTED] [REDACTED] [REDACTED] @gva.es]; [REDACTED] [REDACTED] [REDACTED] @syreon.eu]; [REDACTED] [REDACTED] [REDACTED] @p-95.com]; [REDACTED] [REDACTED] [REDACTED] @merck.com]; [REDACTED] [REDACTED] [REDACTED] @pfizer.com]; [REDACTED] [REDACTED] [REDACTED] @biomerieux.com]; [REDACTED] [REDACTED] [REDACTED] @biomerieux.com]; [REDACTED] [REDACTED] [REDACTED] @fhi.no]; [REDACTED] [REDACTED] [REDACTED] @pfizer.com]; [REDACTED] [REDACTED] [REDACTED] @univ-st-etienne.fr]; [REDACTED] [REDACTED] [REDACTED] @umcg.nl]; [REDACTED] [REDACTED] [REDACTED] @umcg.nl]; [REDACTED] [REDACTED] [REDACTED] @biomerieux.com]; [REDACTED] [REDACTED] [REDACTED] @ucl.ac.uk]; [REDACTED] [REDACTED] [REDACTED] @upmc.fr]; [REDACTED] [REDACTED] [REDACTED] @vaccineseuropa.eu]; [REDACTED] [REDACTED] [REDACTED] @umcutrecht.nl]; [REDACTED] [REDACTED] [REDACTED] @rivm.nl]; [REDACTED] [REDACTED] [REDACTED] @umcutrecht.nl]; [REDACTED] [REDACTED] [REDACTED] @efpia.eu]; [REDACTED] [REDACTED] [REDACTED] @umcutrecht.nl]; [REDACTED] [REDACTED] [REDACTED] @umcg.nl]; [REDACTED] [REDACTED] [REDACTED] @ucl.ac.uk]; [REDACTED] [REDACTED] [REDACTED] @inserm.fr]; [REDACTED] [REDACTED] [REDACTED] @biomerieux.com]; [REDACTED] [REDACTED] [REDACTED] @scinnov.eu]; [REDACTED] [REDACTED] [REDACTED] @gsk.com]; [REDACTED] [REDACTED] [REDACTED] @its.inj.com]; [REDACTED] [REDACTED] [REDACTED] @ipmc.cnrs.fr]; [REDACTED] [REDACTED] [REDACTED] @dr20.cnrs.fr]; [REDACTED] [REDACTED] [REDACTED] @gsk.com]; [REDACTED] [REDACTED] [REDACTED] @gsk.com]; [REDACTED] [REDACTED] [REDACTED] @biomerieux.com]; [REDACTED] [REDACTED] [REDACTED] @gmail.com]; [REDACTED] [REDACTED] [REDACTED] @ssi.dk]; [REDACTED] [REDACTED] [REDACTED] @ssi.dk]; [REDACTED] [REDACTED] [REDACTED] @unife.it]; [REDACTED] [REDACTED] [REDACTED] @uibk.ac.at]; [REDACTED] [REDACTED] [REDACTED] @rivm.nl]; [REDACTED] [REDACTED] [REDACTED] @rivm.nl]; [REDACTED] [REDACTED] [REDACTED] @insem.fr]; [REDACTED] [REDACTED] [REDACTED] @uibk.ac.at]; [REDACTED] [REDACTED] [REDACTED] @rivm.nl]; [REDACTED] [REDACTED] [REDACTED] @univ-st-etienne.fr]; [REDACTED] [REDACTED] [REDACTED] @rivm.nl]; [REDACTED] [REDACTED] [REDACTED] @ucl.ac.uk]; [REDACTED] [REDACTED] [REDACTED] @fhi.no]; [REDACTED] [REDACTED] [REDACTED] @iss.it]; [REDACTED] [REDACTED] [REDACTED] @syreon.eu]; [REDACTED] [REDACTED] [REDACTED] @rivm.nl]; [REDACTED] [REDACTED] [REDACTED] @its.inj.com]; [REDACTED] [REDACTED] [REDACTED] @miha.rs]; [REDACTED] [REDACTED] [REDACTED] @gmail.com]; [REDACTED] [REDACTED] [REDACTED] @univ-st-etienne.fr]; [REDACTED] [REDACTED] [REDACTED] @imperial.ac.uk]; [REDACTED] [REDACTED] [REDACTED] @umcg.nl]; [REDACTED] [REDACTED] [REDACTED] @gmail.com]; [REDACTED] [REDACTED] [REDACTED] @biomerieux.com]; [REDACTED] [REDACTED] [REDACTED] @iss.it]; [REDACTED] [REDACTED] [REDACTED] @syreon.eu]; [REDACTED] [REDACTED] [REDACTED] @rug.nl]; [REDACTED] [REDACTED] [REDACTED] @merck.com]; [REDACTED] [REDACTED] [REDACTED] @iss.it]; [REDACTED] [REDACTED] [REDACTED] @sanofi.com]; [REDACTED] [REDACTED] [REDACTED] @fhi.no]; [REDACTED] [REDACTED] [REDACTED] @gsk.com]; [REDACTED] [REDACTED] [REDACTED] @chu-st-etienne.fr]; [REDACTED] [REDACTED] [REDACTED] @gsk.com]; [REDACTED] [REDACTED] [REDACTED] @fhi.no]; [REDACTED] [REDACTED] [REDACTED] @biomerieux.com]; [REDACTED] [REDACTED] [REDACTED] @rivm.nl]; [REDACTED] [REDACTED] [REDACTED] @gsk.com]; [REDACTED] [REDACTED] [REDACTED] @ssi.dk]; [REDACTED] [REDACTED] [REDACTED] @umcg.nl]; [REDACTED] [REDACTED] [REDACTED] @gva.es]; [REDACTED] [REDACTED] [REDACTED] @iss.it]; [REDACTED] [REDACTED] [REDACTED] @umcg.nl]; [REDACTED] [REDACTED] [REDACTED] @umcutrecht.nl]; [REDACTED] [REDACTED] [REDACTED] @umcg.nl]; [REDACTED] [REDACTED] [REDACTED] @syreon.eu]; [REDACTED] [REDACTED] [REDACTED] @p-95.com]; [REDACTED] [REDACTED] [REDACTED] @uibk.ac.at]; [REDACTED] [REDACTED] [REDACTED] @fhi.no]; [REDACTED] [REDACTED] [REDACTED] @umcutrecht.nl]; [REDACTED] [REDACTED] [REDACTED] @gmail.com]

From: European Commission
 Sent: Tue 9/29/2020 8:18:38 AM
 Subject: COVID-19 Research Manifesto ? your H2020 project 806776-VITAL
 Received: Tue 9/29/2020 8:19:34 AM

Europa / Funding & Tenders Portal notification

Dear Horizon 2020 beneficiaries,

I am glad to inform you that last July **the Commission has launched the [MANIFESTO FOR EU COVID-19 RESEARCH](#)**, to maximise the accessibility of research results in the fight against COVID-19.

The Manifesto is part of the [EU Coronavirus response](#), the common European response to the coronavirus outbreak. It provides guiding principles for beneficiaries of EU research grants for coronavirus prevention, testing, treatment and vaccination to ensure that their research results will be accessible for all and guarantee a return on public investment. This will aim to ensure that no one is left behind in the fight against Covid-19, and that solutions will be developed, produced and deployed to every single corner of the world.

The Manifesto seeks the voluntary support and endorsement from public and private stakeholders benefitting from EU funding, as well as from other research funders and prominent institutions. We are proud for the support we received so far (you can find an updated list of organisations that already endorsed the Manifesto [here](#)) and we believe that even more can be done. I would like then to encourage you [signing the Manifesto](#) as an individual or on behalf of your institution, and so join us in the fight against coronavirus.

By endorsing the Manifesto you commit to

- Make the generated results, whether tangible or intangible, public and accessible without delay, for instance on the [Horizon Results Platform](#), on an existing IP sharing platform, or through an existing patent pool.
- Make scientific papers and research data available in open access without delay and following the [FAIR principles](#) via preprint servers or public repositories, with rights for others to build upon the publications and data and with access to the tools needed for their validation. In particular, make COVID-19 research data available through the [European COVID-19 Data Platform](#).
- Where possible, grant for a limited time, non-exclusive royalty free licences on the intellectual property resulting from EU-funded research. These non-exclusive royalty free licenses shall be given in exchange for the licensees' commitment to rapidly and broadly distribute the resulting products and services under fair and reasonable conditions to prevent, diagnose, treat and contain Covid-19.

Endorsing the Manifesto does not entail legal implications for signed grants. You can find more information in the section dedicated to [Frequently Asked Questions](#).

In case of questions, you can reach us by email: [5.1.2e](#) [@ec.europa.eu](#)

Thank you for your time and once again for your extraordinary contribution to European research and innovation.

Yours,

[5.1.2e](#)

[5.1.2e](#)

This email was sent to the participants of the aforementioned project.